Du Liang, Ning Zhifeng, Zhang Hao, Liu Fuxing
Cancer Research Center, Shantou University Medical College, Shantou, 515031, Guangdong, P. R. China.
Basic Medicine College, Hubei University of Science and Technology, Xianning, 437100, Hubei, P. R. China.
Chin J Cancer. 2017 Mar 9;36(1):28. doi: 10.1186/s40880-017-0193-8.
Worldwide, metastasis is the leading cause of more than 90% of cancer-related deaths. Currently, no specific therapies effectively impede metastasis. Metastatic processes are controlled by complex regulatory networks and transcriptional hierarchy. Corepressor metastasis-associated protein 3 (MTA3) has been confirmed as a novel component of nucleosome remodeling and histone deacetylation (NuRD). Increasing evidence supports the theory that, in the recruitment of transcription factors, coregulators function as master regulators rather than passive passengers. As a master regulator, MTA3 governs the target selection for NuRD and functions as a transcriptional repressor. MTA3 dysregulation is associated with tumor progression, invasion, and metastasis in various cancers. MTA3 is also a key regulator of E-cadherin expression and epithelial-to-mesenchymal transition. Elucidating the functions of MTA3 might help to find additional therapeutic approaches for targeting components of NuRD.
在全球范围内,转移是90%以上癌症相关死亡的主要原因。目前,尚无特效疗法能有效阻止转移。转移过程由复杂的调控网络和转录层次结构控制。共抑制因子转移相关蛋白3(MTA3)已被确认为核小体重塑和组蛋白去乙酰化(NuRD)的一个新组分。越来越多的证据支持这样一种理论,即在转录因子的募集过程中,共调节因子起着主要调节作用,而非被动参与者。作为主要调节因子,MTA3决定NuRD的靶标选择,并作为转录抑制因子发挥作用。MTA3失调与多种癌症的肿瘤进展、侵袭和转移有关联。MTA3也是E-钙黏蛋白表达和上皮-间质转化的关键调节因子。阐明MTA3的功能可能有助于找到针对NuRD组分的其他治疗方法。